Validation of the BCIS-1 myocardial jeopardy score using cardiac magnetic resonance perfusion imaging

Geraint D J Morton1, Kalpa De Silva, Masaki Ishida

  • 1Division of Imaging Sciences, King's College London BHF Centre of Excellence, NIHR Biomedical Research Centre, The Rayne Institute, London, UK. geraint.morton@kcl.ac.uk

Insights

The angiographic BCIS-1 Myocardial Jeopardy Score (BCIS-JS) effectively estimates coronary artery disease (CAD) extent. A score of 6 or higher accurately predicts significant myocardial ischaemic burden, aiding clinical practice.

Area of Science:

  • Cardiology
  • Medical Imaging
  • Diagnostic Accuracy

Background:

  • Coronary artery disease (CAD) assessment is crucial for patient management.
  • The angiographic BCIS-1 Myocardial Jeopardy Score (BCIS-JS) offers a semi-quantitative method to estimate CAD extent.
  • Validation of BCIS-JS against functional ischaemic burden is needed.

Purpose of the Study:

  • To validate the BCIS-JS by assessing its correlation with myocardial ischaemic burden.
  • To evaluate the accuracy of BCIS-JS in predicting a prognostically significant ischaemic threshold.

Main Methods:

  • Seventy-five patients with suspected CAD underwent coronary angiography and high-resolution CMR perfusion imaging.
  • BCIS-JS was calculated and correlated with measured myocardial ischaemic burden.
  • Receiver Operating Characteristic (ROC) curve analysis was used to determine predictive accuracy.

Main Results:

  • A strong correlation was observed between BCIS-JS and myocardial ischaemic burden (r=0.75, P<0.0001).
  • BCIS-JS demonstrated good accuracy in detecting ≥12% myocardial ischaemic burden (AUC=0.87).
  • A BCIS-JS threshold of ≥6 predicted ≥12% ischaemic burden with 91% specificity and 68% sensitivity.

Conclusions:

  • The BCIS-JS correlates well with myocardial ischaemic burden, confirming its functional relevance.
  • A BCIS-JS ≥6 is a specific predictor of the prognostically important 12% ischaemic threshold.
  • BCIS-JS is a valuable tool for classifying CAD burden in clinical trials and practice.